IQWiG’s Nods To Boehringer’s Giotrif and Novartis’ Ultibro Raise Submission Strategy Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany’s IQWiG has cleared Boehringer’s Giotrif for lung cancer and Novartis’ Ultibro Breezhaler for COPD, raising questions as to what HTA submission strategy drugs firms should adopt.